Sen-Jam Pharmaceutical
Growth Stage
Revolutionizing Pain Management with Existing Therapeutics for a $17B Market
Overview
$215,548 - RegCF
$385,548 - Total
$385,548 - Total
Total Commitments ($USD)
Platform
Wefunder
Start Date
06/02/2023
Close Date
04/29/2024
Min. Goal
$150,000
Max. Goal
$3,000,000
Min. Investment
$250
Security Type
Convertible Note
Series
Series A
SEC Filing Type
RegCF
/ RegD 506(c)
Early Bird Val. Cap
$70,000,000
Valuation Cap
$80,000,000
Discount
20%
Rolling Commitments ($USD)
Status
Active
Reporting Date
09/30/2023
Days Remaining
212
% of Min. Goal
144%
% of Max. Goal
7%
Likelihood of Max
Avg. Daily Raise
$1,796
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2C
Margin
Medium
Capital Intensity
Low
Sen-Jam Pharmaceutical, with a valuation of $80 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $3 million. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, intellectual property advancement, and operating expenses.
Summary Profit and Loss Statement
| FY 2022 | FY 2021 | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-3,983,709 |
$-417,348 |
Summary Balance Sheet
| FY 2022 | FY 2021 | |
|---|---|---|
|
Cash |
$181,148 |
$64,694 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$663,018 |
$560,194 |
|
Short-Term Debt |
$1,992,097 |
$47,033 |
|
Long-Term Debt |
$170,896 |
$857,159 |
|
Total Liabilities |
$2,162,993 |
$904,192 |
Financials as of: 06/02/2023
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Sen-Jam Pharmaceutical | 04/29/2024 | Wefunder | $80,000,000 | $385,548 | Convertible Note | Active | RegCF / RegD 506(c) |
| Sen-Jam Pharmaceutical | 04/25/2024 | Dealmaker Securities | - | $0 | Convertible Note | Active | RegD 506(c) |
| Sen-Jam Pharmaceutical | 01/11/2023 | StartEngine | $69,979,019 | $312,093 | Equity - Common | Funded | RegCF |
| Sen-Jam Pharmaceutical | 07/31/2022 | Wefunder | $25,000,000 | $1,008,951 | Convertible Note | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
